Launch week offerEnds in00h00m00s

annual Promonthly Pro

Leonhard Müllauer

Pathologist/Molecular Pathologist/Associate Professor

Medical University of Vienna

Austria

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Austria Professors in Cell Biology Cell Biology professors in Austria

About

Leonhard Müllauer is an Associate Professor at the Medical University of Vienna, Austria. His research primarily focuses on molecular pathology, including the therapeutic effects of drugs in high-grade serous ovarian cancer, gene fusions in juvenile xanthogranuloma, and liquid biopsy disease monitoring for medulloblastoma. He has published extensively on topics such as tumorigenesis in Lynch syndrome and the clinical response to targeted therapies in various malignancies.

Articles (26)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (42)

Hossein Taghizadeh

Karl Landsteiner University of Health Sciences

AUSTRIA

Leonhard Müllauer

Research Interests

Make your next move.

Explore related searches

About

Articles (26)

Tumor-suppressive role of miR-216b impacts cell cycle regulation in high-grade glioma

A single-cell atlas revealing cellular heterogeneity across healthy and diseased human thymus

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumors

Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer

Incidence and Immunopathology of Myositis in Rectal Cancer Patients Treated With Neoadjuvant Immune Checkpoint Inhibitors and Chemoradiotherapy: Findings From the CHINOREC Trial

ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer

Effective targeting of PDGFRA-altered high-grade glioma with avapritinib

Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models

NTRK1 Gene Fusions Are Frequent in Juvenile Xanthogranuloma

Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases

The atypical KRAS&lt;sup&gt;Q22K&lt;/sup&gt; mutation directs TGF-β response towards partial epithelial-to-mesenchymal transition in patient-derived colorectal cancer tumoroids.

Oncogenic gene fusions in cancer

Nfe2l2/NRF2 Deletion Attenuates Tumorigenesis and Increases Bacterial Diversity in a Mouse Model of Lynch Syndrome

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR

Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS

Short‐term and sustained clinical response following thymectomy in patients with myasthenia gravis

Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report.

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Collaborators (42)

Hossein Taghizadeh

Owen Chapman

Joachim Widder

Christoph Gasche

Dan Cacsire Castillo-Tong

Thomas Czech

Ana S. Guerreiro Stucklin

Arul M Chinnaiyan

Matthias Wielscher

Ana-Iris Schiefer

Johannes Laengle

Bernhard Moser

Kristine Jimenez

Daniela Loetsch

Georg Busslinger

Chris Jones

Martin Schepelmann

Amedeo Azizi

Bahil Ghanim

Anna Sophie Berghoff

Cecilia Veraar

Christoph Grimm

Martin Krenn

Georg Widhalm

Hana Palova

Gerwin Heller

Thomas Roetzer-Pejrimovsky

Stephan Polterauer

Natalia Stepien

Andreas Peyrl

Walter Berger

Gerda Egger

Hakan Cetin

Christian Dorfer

Lukas Chavez

Luzia Berchtold

Thomas Bartl

Ulrike Leiss

Andrew Groves

Johannes Gojo

Michaela Lang

Jakob Rath

Make your next move.

The atypical KRAS<sup>Q22K</sup> mutation directs TGF-β response towards partial epithelial-to-mesenchymal transition in patient-derived colorectal cancer tumoroids.